| Literature DB >> 34516248 |
Sydney L Drury1, Anderson R Miller1, Clare L Laut1,2, Alec B Walter3,4, Monique R Bennett1,5, Meng Su6, Mingfeng Bai6,7,8, Bingwen Jing9, Scott B Joseph9, Edward J Metzger9, Charles E Bane9, Chad C Black9, Mary T Macdonald9, Brendan F Dutter10, Ian M Romaine10, Alex G Waterson10,11,12, Gary A Sulikowski10,11,12, E Duco Jansen3,4, James E Crowe1,2,5,13, Richard J Sciotti9, Eric P Skaar1,2.
Abstract
Staphylococcus aureus is a serious threat to public health due to the rise of antibiotic resistance in this organism, which can prolong or exacerbate skin and soft tissue infections (SSTIs). Methicillin-resistant S. aureus is a Gram-positive bacterium and a leading cause of SSTIs. As such, many efforts are under way to develop therapies that target essential biological processes in S. aureus. Antimicrobial photodynamic therapy is an effective alternative to antibiotics; therefore we developed an approach to simultaneously expose S. aureus to intracellular and extracellular photosensitizers. A near infrared photosensitizer was conjugated to human monoclonal antibodies (MAbs) that target the S. aureus iron-regulated surface determinant (Isd) heme acquisition proteins. In addition, the compound VU0038882 was developed to increase photoactivatable porphyrins within the cell. Combinatorial photodynamic treatment of drug-resistant S. aureus exposed to VU0038882 and conjugated anti-Isd MAbs proved to be an effective antibacterial strategy in vitro and in a murine model of SSTIs.Entities:
Keywords: Staphylococcus aureus; antibodies; antimicrobial photodynamic therapy; iron-regulated surface determinant system; photosensitizer; small molecules
Mesh：
Substances：
Year: 2021 PMID： 34516248 PMCID： PMC8597735 DOI： 10.1128/AAC.00919-21
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.938